Previous 10 | Next 10 |
FDA Defers Action on BLA Until Required Inspections Can Be Completed Due to COVID Travel Restrictions, Inspections Could Not Be Completed During Review Period BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on develop...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General...
Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer PR Newswire Randomized Controlled First-Line Gastric Cancer Trial of DKN-01 plus tislelizumab and chemotherapy in collaboration with Bei...
According to unofficial sources, Sequoia China has raised about $9 billion to make investments in China’s healthcare and tech companies, above its $8 billion target. ClinChoice, a US-China-EU clinical CMO, closed a $150 million Series E round financing from China investors. ...
Chinese biotechnology company, BeiGene ( NASDAQ: BGNE ) announced Wednesday an agreement to develop messenger RNA-based therapies in partnership with InnoRNA, a biotech with expertise in LNP-based delivery technology and mRNA drug discovery. Per the terms of the collaborat...
BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs BeiGene will also gain a non-exclusive license to InnoRNA’...
Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones. Shanghai Zai Lab has changed its Hong Kong listing from secondar...
Although the second quarter and first half of 2022 were tough for many companies in the biopharma space, many investors are looking for a turnaround in the second half of the year. A total of 16 new therapies were approved in the first half of the year. Based on recent annual tr...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...